首页|The benefits of PCSK9 inhibitors in patients with acute coronary syndrome:a systematic review and meta-analysis
The benefits of PCSK9 inhibitors in patients with acute coronary syndrome:a systematic review and meta-analysis
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
维普
万方数据
Background:Proprotein convertase subtilisin/kexin 9(PSCK9)inhibitors have been beneficial for many patients with hyperlipidemia.The objective of this study was to investigate the benefit of PSCK9 inhibitors in patients with acute coronary syndrome(ACS).Methods:We systematically searched PubMed,EMBASE,and Cochrane Clinical Trials(published before January 2023;no language restriction)to compare the treatment of patients with ACS using PCSK9 inhibitors and placebo.The primary end points were major ad-verse cardiovascular events,nonfatal myocardial infarction,cardiogenic death,stroke,hospitalization for recurrent ACS,and coronary re-vascularization.Fixed-or random-effects models were used to assess the aggregated data.Results:Of the 1686 identified studies,5 were eligible and included in our analysis(of a total of 38,005 participants,18,609 cases were placed in the PCSK9 inhibitor treatment group and 19,396 cases in the placebo group).Compared with the placebo group,PCSK9 inhib-itors significantly reduced the major adverse cardiovascular events(odds ratio[OR]:0.83;95％confidence interval[Cl]:0.77-0.88;P＜0.00001)for patients following ACS.The incidence of nonfatal myocardial infarction(relative risk:0.80;95％Cl:0.74-0.87;P＜0.00001),cardiovascular death(OR:0.96;95％Cl:0.83-1.10;P=0.56),stroke(OR:0.74;95％Cl:0.63-0.88;P=0.0007),hospi-talization for recurrent ACS(OR:0.57;95％Cl:0.40-0.83;P=0.003),or coronary revascularization(OR:0.82;95％Cl:0.76-0.88;P＜0.00001)all demonstrated a significant decrease in the comparison between the 2 groups.Conclusion:This meta-analysis demonstrated that treatment with PCSK9 inhibitors in patients with ACS reduced the probability of mul-tiple cardiovascular events and improved patient prognosis.
维普
万方数据
